Magnus Asping1, Nis Stride1, Ditte Søgaard1, Tine Lovsø Dohlmann1, Jørn W Helge1, Flemming Dela1,2, Steen Larsen3. 1. Xlab, Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3b, 2200, Copenhagen N, Denmark. 2. Department of Geriatrics, Bispebjerg University Hospital, Copenhagen, Denmark. 3. Xlab, Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3b, 2200, Copenhagen N, Denmark. stelar@sund.ku.dk.
Abstract
BACKGROUND: Statins are used to lower cholesterol in plasma and are one of the most used drugs in the world. Many statin users experience muscle pain, but the mechanisms are unknown at the moment. Many studies have hypothesized that mitochondrial function could be involved in these side effects. AIM: The aim of the study was to investigate mitochondrial function after 2 weeks of treatment with simvastatin (S; n = 10) or pravastatin (P; n = 10) in healthy middle-aged participants. METHODS:Mitochondrial respiratory capacity and substrate sensitivity were measured in permeabilized muscle fibers by high-resolution respirometry. Mitochondrial content (citrate synthase (CS) activity), antioxidant content, as well as coenzyme Q10 concentration (Q10) were determined. Fasting plasma glucose and insulin concentrations were measured, and whole body maximal oxygen uptake (VO2max) was determined. RESULTS: No differences were seen in mitochondrial respiratory capacity although a tendency was observed for a reduction when complex IV respiration was analyzed in both S (229 (169; 289 (95% confidence interval)) vs. 179 (146; 211) pmol/s/mg, respectively; P = 0.062) and P (214 (143; 285) vs. 162 (104; 220) pmol/s/mg, respectively; P = 0.053) after treatment. A tendency (1.64 (1.28; 2.00) vs. 1.28 (0.99; 1.58) mM, respectively; P = 0.092) for an increased mitochondrial substrate sensitivity (complex I-linked substrate; glutamate) was seen only in S after treatment. No differences were seen in Q10, CS activity, or antioxidant content after treatment. Fasting glucose and insulin as well as VO2max were not changed after treatment. CONCLUSION: Two weeks of statin (S or P) treatment have no major effect on mitochondrial function. The tendency for an increased mitochondrial substrate sensitivity after simvastatin treatment could be an early indication of the negative effects linked to statin treatment.
RCT Entities:
BACKGROUND: Statins are used to lower cholesterol in plasma and are one of the most used drugs in the world. Many statin users experience muscle pain, but the mechanisms are unknown at the moment. Many studies have hypothesized that mitochondrial function could be involved in these side effects. AIM: The aim of the study was to investigate mitochondrial function after 2 weeks of treatment with simvastatin (S; n = 10) or pravastatin (P; n = 10) in healthy middle-aged participants. METHODS: Mitochondrial respiratory capacity and substrate sensitivity were measured in permeabilized muscle fibers by high-resolution respirometry. Mitochondrial content (citrate synthase (CS) activity), antioxidant content, as well as coenzyme Q10 concentration (Q10) were determined. Fasting plasma glucose and insulin concentrations were measured, and whole body maximal oxygen uptake (VO2max) was determined. RESULTS: No differences were seen in mitochondrial respiratory capacity although a tendency was observed for a reduction when complex IV respiration was analyzed in both S (229 (169; 289 (95% confidence interval)) vs. 179 (146; 211) pmol/s/mg, respectively; P = 0.062) and P (214 (143; 285) vs. 162 (104; 220) pmol/s/mg, respectively; P = 0.053) after treatment. A tendency (1.64 (1.28; 2.00) vs. 1.28 (0.99; 1.58) mM, respectively; P = 0.092) for an increased mitochondrial substrate sensitivity (complex I-linked substrate; glutamate) was seen only in S after treatment. No differences were seen in Q10, CS activity, or antioxidant content after treatment. Fasting glucose and insulin as well as VO2max were not changed after treatment. CONCLUSION: Two weeks of statin (S or P) treatment have no major effect on mitochondrial function. The tendency for an increased mitochondrial substrate sensitivity after simvastatin treatment could be an early indication of the negative effects linked to statin treatment.
Entities:
Keywords:
Human; Mitochondrial function; Side effects; Skeletal muscle; Statins
Authors: S Larsen; N Stride; M Hey-Mogensen; C N Hansen; J L Andersen; S Madsbad; D Worm; J W Helge; F Dela Journal: Diabetologia Date: 2011-03-18 Impact factor: 10.122
Authors: P Sirvent; O Fabre; S Bordenave; D Hillaire-Buys; E Raynaud De Mauverger; A Lacampagne; J Mercier Journal: Toxicol Appl Pharmacol Date: 2012-01-17 Impact factor: 4.219
Authors: R Laaksonen; K Jokelainen; J Laakso; T Sahi; M Harkonen; M J Tikkanen; J J Himberg Journal: Am J Cardiol Date: 1996-04-15 Impact factor: 2.778
Authors: Andrew J Duncan; Iain P Hargreaves; Maxwell S Damian; John M Land; Simon J R Heales Journal: Toxicol Mech Methods Date: 2009-01 Impact factor: 2.987
Authors: Michael J Knauer; Bradley L Urquhart; Henriette E Meyer zu Schwabedissen; Ute I Schwarz; Christopher J Lemke; Brenda F Leake; Richard B Kim; Rommel G Tirona Journal: Circ Res Date: 2009-11-25 Impact factor: 17.367
Authors: Steen Larsen; Nis Stride; Martin Hey-Mogensen; Christina N Hansen; Lia E Bang; Henning Bundgaard; Lars B Nielsen; Jørn W Helge; Flemming Dela Journal: J Am Coll Cardiol Date: 2013-01-08 Impact factor: 24.094
Authors: Natalie Lefort; Brian Glancy; Benjamin Bowen; Wayne T Willis; Zachary Bailowitz; Elena A De Filippis; Colleen Brophy; Christian Meyer; Kurt Højlund; Zhengping Yi; Lawrence J Mandarino Journal: Diabetes Date: 2010-08-03 Impact factor: 9.461
Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440